PRF Technologies Ltd.PRFX
Price (close)
$0.98
Market cap
$3.4M
P/E
—
Revenue (FY)
$17,000
Net income
-$5.0M
Dividend yield
—
1-year total return
-85.9%
Net margin
-29541.2%
Revenue growth
—
Debt / equity
—
What PRF Technologies Ltd. does.
therapeutics. Our proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief
without the need for repeated dose administration while reducing the potential need for the use of opiates. In March 2025, we acquired
system in order to create extended release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the FDA.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $17,000 |
| Net income | -$4.1M | -$7.2M | -$8.8M | -$9.3M | -$14.6M | -$5.0M |
| Free cash flow | -$2.6M | -$6.6M | -$6.5M | -$6.7M | -$12.6M | -$4.0M |
More on PRFX.
- PRF Technologies Ltd. summary
- PRF Technologies Ltd. financial statements
- PRF Technologies Ltd. key metrics
- PRF Technologies Ltd. health scores and style box
- PRF Technologies Ltd. earnings
- PRF Technologies Ltd. dividends
- PRF Technologies Ltd. valuation
- PRF Technologies Ltd. ownership and insiders
- PRF Technologies Ltd. peers
Figures from PRF Technologies Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.